IN DIA s.r.o. — Clinical Trial Site

16 Registered trials

2 Currently recruiting

Organisation

IN DIA s.r.o.

Location

Lucenec, Slovakia

Identifier

ORG-100046571

Address

Ulica Mieru 1969/1, 984 01, Slovakia

Departments

#3315: Ambulancia vnútorného lekárstva, diabetológie a porúch látkovej premeny a výživy
Ambulancia diabetologie a poruch latkovej premeny a vyzivy
Ambulancia vnutorneho lekarstva
Diabetologická ambulancia
Diabetologická ambulanica
Interná a diabetologická ambulancia
NA
Outpatient Clinic for Internal Medicine and Diabetology, Metabolism and Nutrition Disorders
Practice

Clinical trials at this site (16)

Search interface

A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Unknown

2022-502779-40-99 Primary prevention of atherosclerotic cardiovascular di 5
Obicetrapib Versus Bempedoic Acid to Treat Dyslipidemia in Patients at High to Very High Cardiovascular Risk Recruiting

2025-524265-24-00 Dyslipidemia at High to Very High Cardiovascular Risk 5 2026-05-21
ZENITH: Zilebesiran in Patients with Hypertension Not Adequately Controlled and With Either Established Cardiovascular Disease or High Risk … Recruiting

2025-522960-34-00 Established cardiovascular disease 5 2026-02-09
A Study to Find Out How Safe and Well AZD0780 Works for Adults with High 'Bad' Cholesterol and with Heart- Stroke or Vascular Disease or at … Ended

2025-520521-21-00 Hyperlipidemia 5 2025-09-02
A Study of Lepodisiran (LY3819469) in Adults With Elevated Lipoprotein(a) - ACCLAIM-Lp(a) Ended

2023-509190-23-00 Atherosclerotic Cardiovascular Disease Elevated lp(a) 5 2024-09-03
The Effect of Retatrutide Once Weekly on Cardiovascular Outcomes and Kidney Outcomes in Adults Living With Obesity (TRIUMPH-OUTCOMES) Ended

2023-508630-34-00 Overweight 5 2024-05-28
A Phase III Study to assess efficacy, safety, and tolerability of Zibotentan combined with Dapagliflozin, compared to Dapagliflozin, in pati… Ended

2023-504124-26-00 Chronic Kidney Disease and High Proteinuria 5 2024-04-04
A study to test the effect of BI 456906 on cardiovascular safety in people with overweight or obesity Ended

2022-502442-27-00 Obesity 5 2024-01-08
A randomized, double-blind, placebo-controlled multicenter study to evaluate the effect of inclisiran on preventing major adverse cardiovasc… Ended

2022-502779-40-00 Primary prevention of atherosclerotic cardiovascular di 5 2023-09-04
A Study of Olezarsen (ISIS 678354) Administered Subcutaneously to Participants with Severe Hypertriglyceridemia (SHTG) Ended

2022-501999-26-00 Severe Hypertriglyceridemia (SHTG) 5 2023-07-12
A Placebo-Controlled Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With Atherosclerotic Cardiovascular Disease … Ended

2023-507795-51-00 atherosclerotic heart and blood vessel disease (the nar 5 2022-05-17
A Study of Daily Oral Orforglipron Compared with Insulin Glargine in Participants with Type 2 Diabetes and Obesity or Overweight at Increase… Ended

2022-502833-25-00 Obesity 5 2023-08-02
A Study of Olezarsen Administered Subcutaneously to Participants With Severe Hypertriglyceridemia Ended

2022-501420-20-00 Severe hypertryglyceridemia 5 2023-05-17
A study to learn how well the study treatment asundexian works and how safe it is compared to apixaban to prevent stroke or systemic embolis… Ended

2023-503794-38-00 Prevention of stroke or systemic embolism in atrial fib 5 2022-11-24
A research study to look into how semaglutide, together with a lower dose of insulin glargine, compares to a higher dose of insulin glargine… Ended

2024-510612-75-00 Participants with T2D and overweight 5 2022-08-31
A Study of Tirzepatide (LY3298176) Compared With Dulaglutide on Major Cardiovascular Events in Participants With Type 2 Diabetes (SURPASS-CV… Ended

2023-507846-96-00 Type 2 Diabetes Mellitus 5 2020-06-19